PET of EGFR with64Cu-cetuximab-F(ab′)2in mice with head and neck squamous cell carcinoma xenografts

64Cu-Labeled Inhibitors of Prostate-Specific Membrane Antigen for PET Imaging of Prostate Cancer

(2014) Sangeeta Ray Banerjee et al.   JOURNAL OF MEDICINAL CHEMISTRY

Early Response Monitoring with 18F-FDG PET and Cetuximab-F(ab')2-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model

(2014) L. K. van Dijk et al.   JOURNAL OF NUCLEAR MEDICINE

PET and SPECT Imaging of a Radiolabeled Minigastrin Analogue Conjugated with DOTA, NOTA, and NODAGA and Labeled with 64Cu, 68Ga, and 111In

(2014) S. Roosenburg et al.   MOLECULAR PHARMACEUTICS

The Role of p53 in Combination Radioimmunotherapy with 64Cu-DOTA-Cetuximab and Cisplatin in a Mouse Model of Colorectal Cancer

(2013) Y. Guo et al.   JOURNAL OF NUCLEAR MEDICINE

Imaging of Epidermal Growth Factor Receptor Expression in Head and Neck Cancer with SPECT/CT and 111In-Labeled Cetuximab-F(ab')2

(2013) L. K. van Dijk et al.   JOURNAL OF NUCLEAR MEDICINE

111In-cetuximab-F(ab’)2 SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts

(2013) Laura K. van Dijk et al.   RADIOTHERAPY AND ONCOLOGY

Interaction of EGFR with the tumour microenvironment: Implications for radiation treatment

(2013) Monique M. Nijkamp et al.   RADIOTHERAPY AND ONCOLOGY

Role of EGFR as a prognostic factor for survival in head and neck cancer: a meta-analysis

(2013) Shen Keren et al.   TUMOR BIOLOGY

Review of functional/anatomical imaging in oncology

(2012) Stephanie N. Histed et al.   NUCLEAR MEDICINE COMMUNICATIONS

Evaluation of64Cu-Labeled Bifunctional Chelate–Bombesin Conjugates

(2011) Samia Ait-Mohand et al.   BIOCONJUGATE CHEMISTRY

Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography

(2011) Arifudin Achmad et al.   CANCER SCIENCE

PET of Somatostatin Receptor-Positive Tumors Using 64Cu- and 68Ga-Somatostatin Antagonists: The Chelate Makes the Difference

(2011) M. Fani et al.   JOURNAL OF NUCLEAR MEDICINE

PET imaging of EGFR expression in nude mice bearing MDA-MB-468, a human breast adenocarcinoma

(2011) Kayvan Sadri et al.   NUCLEAR MEDICINE COMMUNICATIONS

Parametric mapping of immunohistochemically stained tissue sections; a method to quantify the colocalization of tumor markers

(2011) Saskia E. Rademakers et al.   CELLULAR ONCOLOGY

Radiolabeled cetuximab: Dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model

(2010) Bianca A.W. Hoeben et al.   INTERNATIONAL JOURNAL OF CANCER

PET of Hypoxia with 89Zr-Labeled cG250-F(ab')2 in Head and Neck Tumors

(2010) B. A. W. Hoeben et al.   JOURNAL OF NUCLEAR MEDICINE

Receptor-Binding, Biodistribution, and Metabolism Studies of 64Cu-DOTA-Cetuximab, a PET-Imaging Agent for Epidermal Growth-Factor Receptor-Positive Tumors

(2008) Wen Ping Li et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Correlating EGFR Expression with Receptor-Binding Properties and Internalization of 64Cu-DOTA-Cetuximab in 5 Cervical Cancer Cell Lines

(2008) M. Eiblmaier et al.   JOURNAL OF NUCLEAR MEDICINE

Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer

(2008) Johan Bussink et al.   LANCET ONCOLOGY